April 7, 2021
See the rest here:
Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer
Related Post
- Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021 - April 14th, 2021
- Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a... - April 14th, 2021
- HOOKIPA Pharma to Present at Kempen Life Science Conference - April 14th, 2021
- Aruna Bio Closes $10.8 Million Common Stock Financing - April 14th, 2021
- Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021 - April 14th, 2021
- BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference - April 14th, 2021
- Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting - April 14th, 2021
- BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema - April 14th, 2021
- Agenus Doses First Cancer Patient with iNKT Cell Therapy - April 14th, 2021
- I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting - April 14th, 2021
- Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE - April 14th, 2021
- CorMedix Has Meeting With FDA on DefenCath Catheter Lock Solution NDA - April 14th, 2021
- Alimera Sciences Receives $20 Million From Ocumension Therapeutics - April 14th, 2021
- Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference - April 14th, 2021
- CohBar to Present at the Mitochondria-Targeted Drug Development Summit - April 14th, 2021
- Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation - April 14th, 2021
- Cosmos Holdings Launches Proprietary King Eros and Queen Venus Supplements for Enhanced Libido - April 14th, 2021
- Primo Nutraceuticals Inc. Corporate Update - April 14th, 2021
- AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government - April 14th, 2021
- Emerging Markets Report: A Moment for the Mushroom - April 14th, 2021
- Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy... - April 12th, 2021
- Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers - April 12th, 2021
- Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss - April 12th, 2021
- Genetic Technologies appoints Mike Tonroe as CFO - April 12th, 2021
- NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or... - April 12th, 2021
- Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders - April 12th, 2021
- Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting - April 12th, 2021
- Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with... - April 12th, 2021
- Senti Bio Presents Preclinical Data from CAR-NK Cell Programs at AACR Virtual Annual Meeting - April 12th, 2021
- Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer - April 12th, 2021
- Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor - April 12th, 2021
- Medexus Announces Conference Participation for April 2021 - April 12th, 2021
- MosaiQ by Quotient Wins Prestigious Red Dot Design Award - April 12th, 2021
- Y-mAbs Announces GPA33-SADA Data Presented at AACR - April 12th, 2021
- SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies - April 12th, 2021
- Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological... - April 12th, 2021
- Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP) - April 12th, 2021
- Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients... - April 12th, 2021
- Revive Adjourns Annual and Special Meeting - April 12th, 2021
- Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial - April 12th, 2021
- Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in... - April 11th, 2021
- Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual... - April 11th, 2021
- Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual... - April 11th, 2021
- MacroGenics Announces Presentations at the 2021 AACR Annual Meeting - April 11th, 2021
- Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR... - April 11th, 2021
- CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function - April 11th, 2021
- Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021 - April 11th, 2021
- iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 - April 11th, 2021
- Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual... - April 11th, 2021
- Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual... - April 11th, 2021
- Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR)... - April 11th, 2021
- TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting - April 11th, 2021
- Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021 - April 11th, 2021
- HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers - April 11th, 2021
- Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types - April 11th, 2021
- Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting - April 11th, 2021
- New Clinical Responses for AGEN1181 Presented at AACR - April 11th, 2021
- C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual... - April 11th, 2021
- PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting... - April 11th, 2021
- Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with... - April 11th, 2021
- Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary... - April 9th, 2021
- NTG Nordic Transport Group A/S - Annual General Meeting 2021 - April 9th, 2021
- Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML) - April 9th, 2021
- 22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee - April 9th, 2021
- Onxeo to Present New Preclinical Data at AACR 2021 - April 9th, 2021
- Tricida to Present at the Needham Virtual Healthcare Conference - April 9th, 2021
- Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 - April 9th, 2021
- Extension of lock-up period in Gilead-Galapagos collaboration agreement - April 9th, 2021
- Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders - April 9th, 2021
- 10x Genomics to Report First Quarter Financial Results on May 5, 2021 - April 9th, 2021
- Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference - April 9th, 2021
- Chinook Therapeutics to Present at Upcoming Investor Conferences - April 9th, 2021
- Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases - April 9th, 2021
- Revive Provides Dial-In Information for Annual and Special Meeting - April 9th, 2021
- Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2 - April 9th, 2021
- Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and... - April 9th, 2021
- Infant Bacterial Therapeutics publishes Annual Report for 2020 - April 9th, 2021
- ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting - April 9th, 2021
- Kiadis employee options committed under the Sanofi Offer - April 9th, 2021
- Cellectis Completes Sale of $47 million through its ATM program - April 9th, 2021
